This retrospective study showed an acceptable efficacy and safety profile of camrelizumab plus chemotherapy or anti-VEGFR2 therapy as a third-line or post-third-line regimen for ES-SCLC. The gene discussed is KDR; the disease is small cell lung carcinoma.